ophthalmologytimes6h
ACELYRIN announces phase 2b/3 trial of izokibep did not meet primary endpoint, ceases further additional internal investment
The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.
Daily1h
Bovhyaluronidase azoximer may reduce exercise intolerance in patients with long-term pulmonary sequelae of COVID-19: Study
III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer ...
Daily11h
Gilead Sciences Seladelpar gets positive CHMP opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
MedPage Today19h
Homing in on Anthracyclines' High-Risk Niche in Early Breast Cancer
A subgroup analysis showed that the benefit in high-risk patients was limited to those with tumors >2 cm, reported Nan Chen, MD, of the University of Chicago, at the San Antonio Breast Cancer ...
The Punch Newspapers18h
Leaders have duty to carry others along – Merit Healthcare MD, Lolu Ojo
The Managing Director of Merit Healthcare Limited, Dr Lolu Ojo, spoke to FAITH AJAYI about his career as a pharmacist and ...
Hosted on MSN17h
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
It’s safe to say that stock investors are closing out 2024 in a rather upbeat mood. The markets posted substantial gains, ...